-
1
-
-
79958114113
-
Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells
-
Yanagisawa M, Yoshimura S, Yu RK. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro. 2011;3.
-
(2011)
ASN Neuro
, pp. 3
-
-
Yanagisawa, M.1
Yoshimura, S.2
Yu, R.K.3
-
2
-
-
34248374867
-
Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs
-
Martinez C, Hofmann TJ, Marino R, et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood. 2007;109:4245-8.
-
(2007)
Blood
, vol.109
, pp. 4245-4248
-
-
Martinez, C.1
Hofmann, T.J.2
Marino, R.3
-
3
-
-
84861801520
-
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
-
Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122:2066-78.
-
(2012)
J Clin Invest
, vol.122
, pp. 2066-2078
-
-
Battula, V.L.1
Shi, Y.2
Evans, K.W.3
-
4
-
-
84875530777
-
Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells
-
Liang YJ, Ding Y, Levery SB, et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A. 2013;110:4968-73.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 4968-4973
-
-
Liang, Y.J.1
Ding, Y.2
Levery, S.B.3
-
5
-
-
0027503907
-
Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - An immunohistochemical study
-
Lammie G, Cheung N, Gerald W, et al. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study. Int J Oncol. 1993;3:909-15.
-
(1993)
Int J Oncol
, vol.3
, pp. 909-915
-
-
Lammie, G.1
Cheung, N.2
Gerald, W.3
-
6
-
-
0022458959
-
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
-
Cheresh DA, Pierschbacher MD, Herzig MA, et al. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102:688-96.
-
(1986)
J Cell Biol
, vol.102
, pp. 688-696
-
-
Cheresh, D.A.1
Pierschbacher, M.D.2
Herzig, M.A.3
-
7
-
-
0017642531
-
VCN-releasable sialic acid and gangliosides in human neuroblastomas
-
Shochat SJ, Abt AB, Schengrund CL. VCN-releasable sialic acid and gangliosides in human neuroblastomas. J Pediatr Surg. 1977;12:413-8.
-
(1977)
J Pediatr Surg
, vol.12
, pp. 413-418
-
-
Shochat, S.J.1
Abt, A.B.2
Schengrund, C.L.3
-
8
-
-
84877805975
-
In silico driven redesign of a clinically relevant antibody for the treatment of gd2 positive tumors
-
Ahmed M, Goldgur Y, Hu J, et al. In silico driven redesign of a clinically relevant antibody for the treatment of gd2 positive tumors. PLoS One. 2013;8:e63359.
-
(2013)
PLoS One
, vol.8
, pp. e63359
-
-
Ahmed, M.1
Goldgur, Y.2
Hu, J.3
-
9
-
-
69049089548
-
The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research
-
Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-37.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5323-5337
-
-
Cheever, M.A.1
Allison, J.P.2
Ferris, A.S.3
-
10
-
-
0027447521
-
Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography
-
Hamilton WB, Helling F, Lloyd KO, et al. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer. 1993;53:566-73.
-
(1993)
Int J Cancer
, vol.53
, pp. 566-573
-
-
Hamilton, W.B.1
Helling, F.2
Lloyd, K.O.3
-
11
-
-
0026690779
-
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas
-
Chang HR, Cordon-Cardo C, Houghton AN, et al. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer. 1992;70:633-8.
-
(1992)
Cancer
, vol.70
, pp. 633-638
-
-
Chang, H.R.1
Cordon-Cardo, C.2
Houghton, A.N.3
-
12
-
-
0023525967
-
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma
-
Heiner JP, Miraldi F, Kallick S, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47:5377-81.
-
(1987)
Cancer Res
, vol.47
, pp. 5377-5381
-
-
Heiner, J.P.1
Miraldi, F.2
Kallick, S.3
-
13
-
-
0036882276
-
Disialoganglioside GD2 and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumor
-
Modak S, Gerald W, Cheung NK. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol. 2002;39:547-51.
-
(2002)
Med Pediatr Oncol
, vol.39
, pp. 547-551
-
-
Modak, S.1
Gerald, W.2
Cheung, N.K.3
-
14
-
-
0030040191
-
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial
-
Grant SC, Kostakoglu L, Kris MG, et al. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med. 1996;23:145-9.
-
(1996)
Eur J Nucl Med
, vol.23
, pp. 145-149
-
-
Grant, S.C.1
Kostakoglu, L.2
Kris, M.G.3
-
16
-
-
0021849979
-
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells
-
Cheung NK, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45:2642-9.
-
(1985)
Cancer Res
, vol.45
, pp. 2642-2649
-
-
Cheung, N.K.1
Saarinen, U.M.2
Neely, J.E.3
-
17
-
-
0023165018
-
Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth
-
Mujoo K, Cheresh DA, Yang HM, et al. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47:1098-104.
-
(1987)
Cancer Res
, vol.47
, pp. 1098-1104
-
-
Mujoo, K.1
Cheresh, D.A.2
Yang, H.M.3
-
18
-
-
77957341503
-
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
-
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-34.
-
(2010)
N Engl J Med
, vol.363
, pp. 1324-1334
-
-
Yu, A.L.1
Gilman, A.L.2
Ozkaynak, M.F.3
-
19
-
-
84877799310
-
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
-
Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1:477-86.
-
(2012)
Oncoimmunology
, vol.1
, pp. 477-486
-
-
Cheung, N.K.1
Guo, H.2
Hu, J.3
-
20
-
-
84909637651
-
Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors
-
Basu EM, Kushner B, Modak S, et al. Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors. Advances in Neuroblastoma Research 2014. Cologne. 2014;POC034.
-
(2014)
Advances in Neuroblastoma Research 2014. Cologne
, pp. POC034
-
-
Basu, E.M.1
Kushner, B.2
Modak, S.3
-
21
-
-
85059207646
-
Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed high-risk neuroblastoma (HR-NB)
-
Kushner B, Cheung IY, Basu EM, et al. Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed high-risk neuroblastoma (HR-NB). Advances in Neuroblastoma Research 2014. Cologne. 2014;POC032.
-
(2014)
Advances in Neuroblastoma Research 2014. Cologne
, pp. POC032
-
-
Kushner, B.1
Cheung, I.Y.2
Basu, E.M.3
-
22
-
-
84856694163
-
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor
-
Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2012;30:426-32.
-
(2012)
J Clin Oncol
, vol.30
, pp. 426-432
-
-
Cheung, I.Y.1
Hsu, K.2
Cheung, N.K.3
-
23
-
-
84865960648
-
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
-
Tarek N, Le Luduec JB, Gallagher MM, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012;122:3260-70.
-
(2012)
J Clin Invest
, vol.122
, pp. 3260-3270
-
-
Tarek, N.1
Le Luduec, J.B.2
Gallagher, M.M.3
-
24
-
-
0023525839
-
Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
-
Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430-40.
-
(1987)
J Clin Oncol
, vol.5
, pp. 1430-1440
-
-
Cheung, N.K.1
Lazarus, H.2
Miraldi, F.D.3
-
25
-
-
0024247485
-
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
-
Brodeur G, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874-81.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1874-1881
-
-
Brodeur, G.1
Seeger, R.C.2
Barrett, A.3
-
26
-
-
0026547712
-
Reassessment of patient response to monoclonal antibody 3F8
-
Cheung NV, Lazarus H, Miraldi FD, et al. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol. 1992;10:671-2.
-
(1992)
J Clin Oncol
, vol.10
, pp. 671-672
-
-
Cheung, N.V.1
Lazarus, H.2
Miraldi, F.D.3
-
27
-
-
79952762286
-
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: A phase I study
-
Kushner BH, Kramer K, Modak S, et al. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol. 2011;29:1168-74.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1168-1174
-
-
Kushner, B.H.1
Kramer, K.2
Modak, S.3
-
28
-
-
0031686971
-
Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
-
Cheung NK, Kushner BH, Cheung IY, et al. Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053-60.
-
(1998)
J Clin Oncol
, vol.16
, pp. 3053-3060
-
-
Cheung, N.K.1
Kushner, B.H.2
Cheung, I.Y.3
-
29
-
-
0024358410
-
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma
-
Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73:1936-41.
-
(1989)
Blood
, vol.73
, pp. 1936-1941
-
-
Kushner, B.H.1
Cheung, N.K.2
-
30
-
-
0035890643
-
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
-
Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189-94.
-
(2001)
J Clin Oncol
, vol.19
, pp. 4189-4194
-
-
Kushner, B.H.1
Kramer, K.2
Cheung, N.K.3
-
31
-
-
23944499069
-
Detecting minimal residual disease in neuroblastoma patients - The present state of the art
-
Beiske K, Ambros PF, Burchill SA, et al. Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett. 2005;228:229-40.
-
(2005)
Cancer Lett
, vol.228
, pp. 229-240
-
-
Beiske, K.1
Ambros, P.F.2
Burchill, S.A.3
-
32
-
-
33745528911
-
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
-
Cheung NK, Sowers R, Vickers AJ, et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2006;24:2885-90.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2885-2890
-
-
Cheung, N.K.1
Sowers, R.2
Vickers, A.J.3
-
33
-
-
84906234428
-
Key role for myeloid cells: Phase II results of anti-G antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
-
PMID:24644014
-
Cheung NK, Cheung IY, Kramer K, et al. Key role for myeloid cells: phase II results of anti-G antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014 PMID:24644014.
-
(2014)
Int J Cancer
-
-
Cheung, N.K.1
Cheung, I.Y.2
Kramer, K.3
-
34
-
-
84866623753
-
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
-
Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264-70.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3264-3270
-
-
Cheung, N.K.1
Cheung, I.Y.2
Kushner, B.H.3
-
36
-
-
0036035607
-
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
-
Cheung NK, Modak S, Vickers A, et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51:557-64.
-
(2002)
Cancer Immunol Immunother
, vol.51
, pp. 557-564
-
-
Cheung, N.K.1
Modak, S.2
Vickers, A.3
-
37
-
-
84886945545
-
Anti-GD2 antibody 3F8 and barley-derived (1 - > 3),(1 - > 4)-beta-glucan: A phase I study in patients with chemoresistant neuroblastoma
-
Modak S, Kushner BH, Kramer K, et al. Anti-GD2 antibody 3F8 and barley-derived (1 - > 3),(1 - > 4)-beta-glucan: a phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology. 2013;2:e23402.
-
(2013)
Oncoimmunology
, vol.2
, pp. e23402
-
-
Modak, S.1
Kushner, B.H.2
Kramer, K.3
-
39
-
-
85059207549
-
Phase I study of haploidentical natural killer (NK) cells plus monoclonal antibody 3F8 for resistant high-risk neuroblastom (HR-NB)
-
Modak M, Cheung NK, Kushner B, et al. Phase I study of haploidentical natural killer (NK) cells plus monoclonal antibody 3F8 for resistant high-risk neuroblastom (HR-NB). Advances in Neuroblastoma Research 2014. Cologne. 2014;OR075.
-
(2014)
Advances in Neuroblastoma Research 2014. Cologne
, pp. OR075
-
-
Modak, M.1
Cheung, N.K.2
Kushner, B.3
-
40
-
-
0027145882
-
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors
-
Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12:184-93.
-
(1994)
J Clin Oncol
, vol.12
, pp. 184-193
-
-
Murray, J.L.1
Cunningham, J.E.2
Brewer, H.3
-
41
-
-
0030929898
-
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group
-
Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 1997;80:317-33.
-
(1997)
Cancer
, vol.80
, pp. 317-333
-
-
Frost, J.D.1
Hank, J.A.2
Reaman, G.H.3
-
42
-
-
0023147836
-
Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity
-
Thurin J, Thurin M, Kimoto Y, et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res. 1987;47:1229-33.
-
(1987)
Cancer Res
, vol.47
, pp. 1229-1233
-
-
Thurin, J.1
Thurin, M.2
Kimoto, Y.3
-
43
-
-
0024586486
-
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides
-
Iliopoulos D, Ernst C, Steplewski Z, et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440-4.
-
(1989)
J Natl Cancer Inst
, vol.81
, pp. 440-444
-
-
Iliopoulos, D.1
Ernst, C.2
Steplewski, Z.3
-
44
-
-
0025021639
-
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody
-
Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382-6.
-
(1990)
J Immunol
, vol.144
, pp. 1382-1386
-
-
Mueller, B.M.1
Romerdahl, C.A.2
Gillies, S.D.3
-
45
-
-
0026549233
-
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
-
Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3:19-24.
-
(1992)
Hum Antibodies Hybridomas
, vol.3
, pp. 19-24
-
-
Saleh, M.N.1
Khazaeli, M.B.2
Wheeler, R.H.3
-
46
-
-
0028946423
-
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
-
Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261-7.
-
(1995)
Eur J Cancer
, vol.31 A
, pp. 261-267
-
-
Handgretinger, R.1
Anderson, K.2
Lang, P.3
-
47
-
-
0031750167
-
Phase I trial of a human-mouse chimeric antidisialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma
-
Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric antidisialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-80.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2169-2180
-
-
Yu, A.L.1
Uttenreuther-Fischer, M.M.2
Huang, C.S.3
-
48
-
-
4444371613
-
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
-
Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22:3549-57.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3549-3557
-
-
Simon, T.1
Hero, B.2
Faldum, A.3
-
49
-
-
78651428141
-
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
-
Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.
-
(2011)
BMC Cancer
, vol.11
, pp. 21
-
-
Simon, T.1
Hero, B.2
Faldum, A.3
-
50
-
-
0034671441
-
Phase I study of chimeric human/murine anti-ganglioside G (D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study
-
Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G (D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000;18:4077-85.
-
(2000)
J Clin Oncol
, vol.18
, pp. 4077-4085
-
-
Ozkaynak, M.F.1
Sondel, P.M.2
Krailo, M.D.3
-
51
-
-
0000230036
-
Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study
-
Yu AL BA, Alvarado C, Rao VJ, Castleberry RP. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc Am Soc Clin Oncol. 1997;16.
-
(1997)
Proc Am Soc Clin Oncol
, pp. 16
-
-
Yu, A.L.1
B, A.2
Alvarado, C.3
Rao, V.J.4
Castleberry, R.P.5
-
52
-
-
8944242603
-
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma
-
Murray JL, Kleinerman ES, Jia SF, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996;19:206-17.
-
(1996)
J Immunother Emphasis Tumor Immunol
, vol.19
, pp. 206-217
-
-
Murray, J.L.1
Kleinerman, E.S.2
Jia, S.F.3
-
53
-
-
0030756133
-
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients
-
Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res. 1997;3:1277-88.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 1277-1288
-
-
Albertini, M.R.1
Hank, J.A.2
Schiller, J.H.3
-
54
-
-
84883875530
-
Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: A SIOPEN phase 1 study
-
Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: a SIOPEN phase 1 study. MAbs. 2013;5:801-9.
-
(2013)
MAbs
, vol.5
, pp. 801-809
-
-
Ladenstein, R.1
Weixler, S.2
Baykan, B.3
-
55
-
-
85059207042
-
Evaluation of clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with subcutaneous interleukin-2 in a single center treatment program in high-risk neuroblastoma
-
Lode H, Muller I. Evaluation of clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with subcutaneous interleukin-2 in a single center treatment program in high-risk neuroblastoma. Advances in Neuroblastoma Research 2014. Cologne. 2014;PL010.
-
(2014)
Advances in Neuroblastoma Research 2014. Cologne
, pp. PL010
-
-
Lode, H.1
Muller, I.2
-
56
-
-
33645280860
-
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
-
Choi BS, Sondel PM, Hank JA, et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006;55:761-74.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 761-774
-
-
Choi, B.S.1
Sondel, P.M.2
Hank, J.A.3
-
57
-
-
84902962349
-
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma
-
2014
-
Navid F, Sondel PM, Barfield R, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;32:1445-52, 2014.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1445-1452
-
-
Navid, F.1
Sondel, P.M.2
Barfield, R.3
-
58
-
-
85059207089
-
Phase I trial of anti-GD2 humanized 3F8 monoclonal antibody (MAb) combined with subcutaneous interleukin-2 (scIL2) in patients with relapsed neuroblastoma or other GD2-positive solid tumors
-
Roberts SS, Chou AJ, Basu EM, et al. Phase I trial of anti-GD2 humanized 3F8 monoclonal antibody (MAb) combined with subcutaneous interleukin-2 (scIL2) in patients with relapsed neuroblastoma or other GD2-positive solid tumors. Advances in Neuroblastoma Research 2014. Cologne. 2014;POC027.
-
(2014)
Advances in Neuroblastoma Research 2014. Cologne
, pp. POC027
-
-
Roberts, S.S.1
Chou, A.J.2
Basu, E.M.3
-
59
-
-
85059207554
-
Pharmacokinetics of humanized anti-GD2 monoclonal antibody Hu3F8 in patients with metastatic GD2-positive tumors
-
Cheung IY, Basu EM, Modak M, et al. Pharmacokinetics of humanized anti-GD2 monoclonal antibody Hu3F8 in patients with metastatic GD2-positive tumors. Advances in Neuroblastoma Research 2014. Cologne. 2014;POC037.
-
(2014)
Advances in Neuroblastoma Research 2014. Cologne
, pp. POC037
-
-
Cheung, I.Y.1
Basu, E.M.2
Modak, M.3
-
60
-
-
0033928328
-
Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma
-
Cheung NK, Guo HF, Heller G, et al. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res. 2000;6:2653-60.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2653-2660
-
-
Cheung, N.K.1
Guo, H.F.2
Heller, G.3
-
61
-
-
0033958915
-
Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2
-
Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 2000;18:376-84.
-
(2000)
J Clin Oncol
, vol.18
, pp. 376-384
-
-
Foon, K.A.1
Lutzky, J.2
Baral, R.N.3
-
62
-
-
0027336381
-
Disialoganglioside GD2 anti-idiotypic monoclonal antibodies
-
Cheung NK, Canete A, Cheung IY, et al. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer. 1993;54:499-505.
-
(1993)
Int J Cancer
, vol.54
, pp. 499-505
-
-
Cheung, N.K.1
Canete, A.2
Cheung, I.Y.3
-
63
-
-
70350026879
-
Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma
-
Bleeke M, Fest S, Huebener N, et al. Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma. Eur J Cancer. 2009;45:2915-21.
-
(2009)
Eur J Cancer
, vol.45
, pp. 2915-2921
-
-
Bleeke, M.1
Fest, S.2
Huebener, N.3
-
64
-
-
20244378964
-
DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses
-
Bolesta E, Kowalczyk A, Wierzbicki A, et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 2005;65:3410-8.
-
(2005)
Cancer Res
, vol.65
, pp. 3410-3418
-
-
Bolesta, E.1
Kowalczyk, A.2
Wierzbicki, A.3
-
65
-
-
10744226998
-
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
-
Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9:5214-20.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 5214-5220
-
-
Ragupathi, G.1
Livingston, P.O.2
Hood, C.3
-
66
-
-
84895814045
-
Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission
-
Kushner BH, Cheung IY, Modak S, et al. Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res. 2014;20(5):1375-82.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.5
, pp. 1375-1382
-
-
Kushner, B.H.1
Cheung, I.Y.2
Modak, S.3
-
67
-
-
33645679838
-
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
-
Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006;12:1750-9.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1750-1759
-
-
Osenga, K.L.1
Hank, J.A.2
Albertini, M.R.3
-
68
-
-
79951886003
-
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study
-
Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010;28:4969-75.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4969-4975
-
-
Shusterman, S.1
London, W.B.2
Gillies, S.D.3
-
69
-
-
0030453784
-
Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy
-
Becker JC, Varki N, Gillies SD, et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest. 1996;98:2801-4.
-
(1996)
J Clin Invest
, vol.98
, pp. 2801-2804
-
-
Becker, J.C.1
Varki, N.2
Gillies, S.D.3
-
70
-
-
84865410508
-
Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention
-
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012;189:2656-64.
-
(2012)
J Immunol
, vol.189
, pp. 2656-2664
-
-
Yang, R.K.1
Kalogriopoulos, N.A.2
Rakhmilevich, A.L.3
-
71
-
-
84870975998
-
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
-
Albertini MR, Hank JA, Gadbaw B, et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012;61(12):2261-2271.
-
(2012)
Cancer Immunol Immunother
, vol.61
, Issue.12
, pp. 2261-2271
-
-
Albertini, M.R.1
Hank, J.A.2
Gadbaw, B.3
-
72
-
-
84855804372
-
Interleukin-15 biology and its therapeutic implications in cancer
-
Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012;33:35-41.
-
(2012)
Trends Pharmacol Sci
, vol.33
, pp. 35-41
-
-
Steel, J.C.1
Waldmann, T.A.2
Morris, J.C.3
-
73
-
-
0036625059
-
Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis
-
Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood. 2002;99:4166-73.
-
(2002)
Blood
, vol.99
, pp. 4166-4173
-
-
Metelitsa, L.S.1
Gillies, S.D.2
Super, M.3
-
74
-
-
80052601578
-
Use of NK cell activity in cure by transplant
-
Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. 2011;155:14-29.
-
(2011)
Br J Haematol
, vol.155
, pp. 14-29
-
-
Leung, W.1
-
75
-
-
78649968328
-
Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy
-
Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70:9554-61.
-
(2010)
Cancer Res
, vol.70
, pp. 9554-9561
-
-
Delgado, D.C.1
Hank, J.A.2
Kolesar, J.3
-
76
-
-
0026511704
-
Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity
-
Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood. 1992;79:1484-90.
-
(1992)
Blood
, vol.79
, pp. 1484-1490
-
-
Kushner, B.H.1
Cheung, N.K.2
-
77
-
-
0344327143
-
Therapeutic intervention with complement and beta-glucan in cancer
-
Ross GD, Vetvicka V, Yan J, et al. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology. 1999;42:61-74.
-
(1999)
Immunopharmacology
, vol.42
, pp. 61-74
-
-
Ross, G.D.1
Vetvicka, V.2
Yan, J.3
-
78
-
-
0027398448
-
A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen
-
Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol. 1993;120:545-56.
-
(1993)
J Cell Biol
, vol.120
, pp. 545-556
-
-
Diamond, M.S.1
Springer, T.A.2
-
79
-
-
0035999738
-
Oral (1 -> 3),(1 -> 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma
-
Cheung NK, Modak S. Oral (1 -> 3),(1 -> 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8:1217-23.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1217-1223
-
-
Cheung, N.K.1
Modak, S.2
-
80
-
-
2942593696
-
Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma
-
Ren Y, Chan HM, Li Z, et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene. 2004;23:4146-54.
-
(2004)
Oncogene
, vol.23
, pp. 4146-4154
-
-
Ren, Y.1
Chan, H.M.2
Li, Z.3
-
81
-
-
77956976681
-
Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm
-
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-96.
-
(2010)
Nat Immunol
, vol.11
, pp. 889-896
-
-
Biswas, S.K.1
Mantovani, A.2
-
82
-
-
0024378215
-
Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated anti-tumor cytotoxicity not detected by isotope release assays
-
Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated anti-tumor cytotoxicity not detected by isotope release assays. J Exp Med. 1989;170:511-26.
-
(1989)
J Exp Med
, vol.170
, pp. 511-526
-
-
Munn, D.H.1
Cheung, N.K.2
-
83
-
-
79952090734
-
Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion
-
Ladenstein R, Potschger U, Siabalis D, et al. Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion. J Clin Oncol. 2011;29:441-8.
-
(2011)
J Clin Oncol
, vol.29
, pp. 441-448
-
-
Ladenstein, R.1
Potschger, U.2
Siabalis, D.3
-
84
-
-
70350511426
-
Safety and immunologic effects of IL-15 administration in non-human primates
-
Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in non-human primates. Blood. 2009;114:2417-26.
-
(2009)
Blood
, vol.114
, pp. 2417-2426
-
-
Berger, C.1
Berger, M.2
Hackman, R.C.3
-
85
-
-
2442547655
-
Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2
-
Metelitsa LS, Wu HW, Wang H, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199:1213-21.
-
(2004)
J Exp Med
, vol.199
, pp. 1213-1221
-
-
Metelitsa, L.S.1
Wu, H.W.2
Wang, H.3
-
86
-
-
84861801527
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity
-
Liu D, Song L, Wei J, et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012;122:2221-33.
-
(2012)
J Clin Invest
, vol.122
, pp. 2221-2233
-
-
Liu, D.1
Song, L.2
Wei, J.3
-
87
-
-
33644975335
-
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins
-
Mortier E, Quemener A, Vusio P, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 2006;281:1612-9.
-
(2006)
J Biol Chem
, vol.281
, pp. 1612-1619
-
-
Mortier, E.1
Quemener, A.2
Vusio, P.3
-
88
-
-
84877964989
-
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its anti-tumor potency
-
Vincent M, Bessard A, Cochonneau D, et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its anti-tumor potency. Int J Cancer. 2013;133:757-65.
-
(2013)
Int J Cancer
, vol.133
, pp. 757-765
-
-
Vincent, M.1
Bessard, A.2
Cochonneau, D.3
-
89
-
-
84877809580
-
Current concepts in MRI of focal and diffuse malignancy of bone marrow
-
Howe BM, Johnson GB, Wenger DE. Current concepts in MRI of focal and diffuse malignancy of bone marrow. Semin Musculoskelet Radiol. 2013;17:137-44.
-
(2013)
Semin Musculoskelet Radiol
, vol.17
, pp. 137-144
-
-
Howe, B.M.1
Johnson, G.B.2
Wenger, D.E.3
-
90
-
-
33947688082
-
Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion
-
Qian J, Liu T, Yang L, et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 2007;364:8-18.
-
(2007)
Anal Biochem
, vol.364
, pp. 8-18
-
-
Qian, J.1
Liu, T.2
Yang, L.3
-
91
-
-
0027367160
-
One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody
-
Galili U, Anaraki F, Thall A, et al. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood. 1993;82:2485-93.
-
(1993)
Blood
, vol.82
, pp. 2485-2493
-
-
Galili, U.1
Anaraki, F.2
Thall, A.3
-
92
-
-
0036872920
-
Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum
-
Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation. 2002;9:376-81.
-
(2002)
Xenotransplantation
, vol.9
, pp. 376-381
-
-
Zhu, A.1
Hurst, R.2
-
93
-
-
80051811754
-
Fatal infusion reaction to cetuximab: The need for predictive risk factors and safer patient selection
-
Tronconi MC, Sclafani F, Rimassa L, et al. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. J Clin Oncol. 2011;29:e680-1.
-
(2011)
J Clin Oncol
, vol.29
, pp. e680-e681
-
-
Tronconi, M.C.1
Sclafani, F.2
Rimassa, L.3
-
94
-
-
79960215653
-
Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains
-
Lammerts van Bueren JJ, Rispens T, Verploegen S, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29:574-6.
-
(2011)
Nat Biotechnol
, vol.29
, pp. 574-576
-
-
Lammerts Van Bueren, J.J.1
Rispens, T.2
Verploegen, S.3
-
96
-
-
80053082300
-
A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity
-
Alvarez-Rueda N, Desselle A, Cochonneau D, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE. 2011;6:e25220.
-
(2011)
PLoS ONE
, vol.6
, pp. e25220
-
-
Alvarez-Rueda, N.1
Desselle, A.2
Cochonneau, D.3
-
97
-
-
84906085030
-
Antibody drug conjugates
-
Teicher BA. Antibody drug conjugates. Curr Opin Oncol. 2014;26:476-83.
-
(2014)
Curr Opin Oncol
, vol.26
, pp. 476-483
-
-
Teicher, B.A.1
-
98
-
-
84892369775
-
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
-
Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588:288-97.
-
(2014)
FEBS Lett
, vol.588
, pp. 288-297
-
-
Ahmed, M.1
Cheung, N.K.2
-
99
-
-
64649084383
-
Radiation-induced bystander signalling in cancer therapy
-
Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009;9:351-60.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 351-360
-
-
Prise, K.M.1
O'Sullivan, J.M.2
-
100
-
-
0008942168
-
Monoclonal antibodies: Basic principles - Radioisotope conjugates
-
DeVita VT, Hellman S, Rosenberg SA, editors. Philadelphia: Lippincott
-
Larson SM, Divgi C, Sgouros G, et al. Monoclonal antibodies: basic principles - radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer - principles and practice. Philadelphia: Lippincott; 2000. p. 396-412.
-
(2000)
Biologic Therapy of Cancer - Principles and Practice
, pp. 396-412
-
-
Larson, S.M.1
Divgi, C.2
Sgouros, G.3
-
101
-
-
77957200514
-
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
-
Croog VJ, Kramer K, Cheung NK, et al. Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2010;78(3):849-54.
-
(2010)
Int J Radiat Oncol Biol Phys
, vol.78
, Issue.3
, pp. 849-854
-
-
Croog, V.J.1
Kramer, K.2
Cheung, N.K.3
-
103
-
-
36849018928
-
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
-
Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465-70.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5465-5470
-
-
Kramer, K.1
Humm, J.L.2
Souweidane, M.M.3
-
104
-
-
77953288400
-
Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma
-
Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97:409-18.
-
(2010)
J Neurooncol
, vol.97
, pp. 409-418
-
-
Kramer, K.1
Kushner, B.H.2
Modak, S.3
-
105
-
-
79551688075
-
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging
-
Orcutt KD, Slusarczyk AL, Cieslewicz M, et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol. 2011;38:223-33.
-
(2011)
Nucl Med Biol
, vol.38
, pp. 223-233
-
-
Orcutt, K.D.1
Slusarczyk, A.L.2
Cieslewicz, M.3
-
106
-
-
84893690105
-
The potential and hurdles of targeted alpha therapy - Clinical trials and beyond
-
Elgqvist J, Frost S, Pouget JP, et al. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 2014;3:324.
-
(2014)
Front Oncol
, vol.3
, pp. 324
-
-
Elgqvist, J.1
Frost, S.2
Pouget, J.P.3
-
107
-
-
6044248953
-
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
-
Miederer M, McDevitt MR, Borchardt P, et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res. 2004;10:6985-92.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 6985-6992
-
-
Miederer, M.1
McDevitt, M.R.2
Borchardt, P.3
-
108
-
-
0025133413
-
Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy
-
Rotmensch J, Roeske J, Chen G, et al. Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy. Gynecol Oncol. 1990;38:478-85.
-
(1990)
Gynecol Oncol
, vol.38
, pp. 478-485
-
-
Rotmensch, J.1
Roeske, J.2
Chen, G.3
-
109
-
-
79551511102
-
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
-
He P, Kramer K, Smith-Jones P, et al. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. Eur J Nucl Med Mol Imaging. 2011;38:334-42.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 334-342
-
-
He, P.1
Kramer, K.2
Smith-Jones, P.3
-
110
-
-
68249160655
-
A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases
-
Lv Y, Cheung NK, Fu BM. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases. J Nucl Med. 2009;50:1324-31.
-
(2009)
J Nucl Med
, vol.50
, pp. 1324-1331
-
-
Lv, Y.1
Cheung, N.K.2
Fu, B.M.3
-
111
-
-
33644869654
-
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
-
Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-34.
-
(2006)
J Clin Oncol
, vol.24
, pp. 823-834
-
-
Goldenberg, D.M.1
Sharkey, R.M.2
Paganelli, G.3
-
112
-
-
84904174507
-
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex
-
Cheal SM, Xu H, Guo HF, et al. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014;13:1803-12.
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 1803-1812
-
-
Cheal, S.M.1
Xu, H.2
Guo, H.F.3
-
113
-
-
2642527143
-
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2
-
Cheung NK, Modak S, Lin Y, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med. 2004;45:867-77.
-
(2004)
J Nucl Med
, vol.45
, pp. 867-877
-
-
Cheung, N.K.1
Modak, S.2
Lin, Y.3
-
114
-
-
0037401058
-
In vitro and in vivo anti-tumor activity of liposomal Fenretinide targeted to human neuroblastoma
-
Raffaghello L, Pagnan G, Pastorino F, et al. In vitro and in vivo anti-tumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer. 2003;104:559-67.
-
(2003)
Int J Cancer
, vol.104
, pp. 559-567
-
-
Raffaghello, L.1
Pagnan, G.2
Pastorino, F.3
-
115
-
-
0037224431
-
Doxorubicin-loaded Fab' fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice
-
Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003;63:86-92.
-
(2003)
Cancer Res
, vol.63
, pp. 86-92
-
-
Pastorino, F.1
Brignole, C.2
Marimpietri, D.3
-
116
-
-
3543119461
-
Immune cell-mediated anti-tumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs
-
Brignole C, Pastorino F, Marimpietri D, et al. Immune cell-mediated anti-tumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst. 2004;96:1171-80.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 1171-1180
-
-
Brignole, C.1
Pastorino, F.2
Marimpietri, D.3
-
117
-
-
84861473531
-
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles
-
Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7:e38129.
-
(2012)
PLoS ONE
, vol.7
, pp. e38129
-
-
Tivnan, A.1
Orr, W.S.2
Gubala, V.3
-
118
-
-
34249812122
-
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
-
Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017-22.
-
(2007)
Oncogene
, vol.26
, pp. 5017-5022
-
-
Welch, C.1
Chen, Y.2
Stallings, R.L.3
-
119
-
-
42049092138
-
Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest
-
Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564-8.
-
(2008)
FEBS Lett
, vol.582
, pp. 1564-1568
-
-
Sun, F.1
Fu, H.2
Liu, Q.3
-
120
-
-
77953920780
-
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
-
Pang RT, Leung CO, Ye TM, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010;31:1037-44.
-
(2010)
Carcinogenesis
, vol.31
, pp. 1037-1044
-
-
Pang, R.T.1
Leung, C.O.2
Ye, T.M.3
-
121
-
-
84885124167
-
Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma
-
Di Paolo D, Pastorino F, Zuccari G, et al. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. J Control Release. 2013;170:445-51.
-
(2013)
J Control Release
, vol.170
, pp. 445-451
-
-
Di Paolo, D.1
Pastorino, F.2
Zuccari, G.3
-
122
-
-
79953697128
-
Anti-neuroblastoma activity of gold nanorods bound with GD2 monoclonal antibody under near-infrared laser irradiation
-
Peng CA, Wang CH. Anti-neuroblastoma activity of gold nanorods bound with GD2 monoclonal antibody under near-infrared laser irradiation. Cancers (Basel). 2011;3:227-40.
-
(2011)
Cancers (Basel)
, vol.3
, pp. 227-240
-
-
Peng, C.A.1
Wang, C.H.2
-
123
-
-
67849086444
-
In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody
-
Wang CH, Huang YJ, Chang CW, et al. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody. Nanotechnology. 2009;20:315101.
-
(2009)
Nanotechnology
, vol.20
, pp. 315101
-
-
Wang, C.H.1
Huang, Y.J.2
Chang, C.W.3
-
124
-
-
33845294816
-
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and anti-tumor efficacy of adoptively transferred T cells
-
Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and anti-tumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995-1004.
-
(2006)
Cancer Res
, vol.66
, pp. 10995-11004
-
-
Kowolik, C.M.1
Topp, M.S.2
Gonzalez, S.3
-
125
-
-
62549097817
-
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
-
Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360-5.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 3360-3365
-
-
Carpenito, C.1
Milone, M.C.2
Hassan, R.3
-
126
-
-
55549145071
-
Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and anti-tumor activity in individuals with neuroblastoma
-
Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and anti-tumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-70.
-
(2008)
Nat Med
, vol.14
, pp. 1264-1270
-
-
Pule, M.A.1
Savoldo, B.2
Myers, G.D.3
-
127
-
-
82955207691
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
-
Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6.
-
(2011)
Blood
, vol.118
, pp. 6050-6056
-
-
Louis, C.U.1
Savoldo, B.2
Dotti, G.3
-
128
-
-
84883192533
-
Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging
-
Liebsch L, Kailayangiri S, Beck L, et al. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer. 2013;109:658-66.
-
(2013)
Br J Cancer
, vol.109
, pp. 658-666
-
-
Liebsch, L.1
Kailayangiri, S.2
Beck, L.3
-
129
-
-
84856267795
-
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
-
Esser R, Muller T, Stefes D, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med. 2012;16:569-81.
-
(2012)
J Cell Mol Med
, vol.16
, pp. 569-581
-
-
Esser, R.1
Muller, T.2
Stefes, D.3
-
130
-
-
17644385543
-
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
-
Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98-104.
-
(2005)
Int J Cancer
, vol.115
, pp. 98-104
-
-
Hoffmann, P.1
Hofmeister, R.2
Brischwein, K.3
-
131
-
-
49649120397
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
-
Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-7.
-
(2008)
Science
, vol.321
, pp. 974-977
-
-
Bargou, R.1
Leo, E.2
Zugmaier, G.3
-
132
-
-
84921332022
-
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy
-
PMID:24895182
-
Cheng M, Ahmed M, Xu H, et al. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer. 2014 PMID:24895182.
-
(2014)
Int J Cancer
-
-
Cheng, M.1
Ahmed, M.2
Xu, H.3
-
134
-
-
84867375009
-
Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
-
Yankelevich M, Kondadasula SV, Thakur A, et al. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012;59(7):1198-205.
-
(2012)
Pediatr Blood Cancer
, vol.59
, Issue.7
, pp. 1198-1205
-
-
Yankelevich, M.1
Kondadasula, S.V.2
Thakur, A.3
-
135
-
-
84865115651
-
Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect
-
Eissler N, Ruf P, Mysliwietz J, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 2012;72:3958-66.
-
(2012)
Cancer Res
, vol.72
, pp. 3958-3966
-
-
Eissler, N.1
Ruf, P.2
Mysliwietz, J.3
|